Share on StockTwits

Integra Lifesciences Holdings Corp (NASDAQ:IART) VP Richard D. Gorelick sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $50.03, for a total value of $350,210.00. Following the completion of the sale, the vice president now directly owns 13,597 shares of the company’s stock, valued at approximately $680,258. The transaction was disclosed in a filing with the SEC, which is available at this link.

Integra Lifesciences Holdings Corp (NASDAQ:IART) traded down 0.70% during mid-day trading on Thursday, hitting $49.66. The stock had a trading volume of 81,190 shares. Integra Lifesciences Holdings Corp has a 1-year low of $37.92 and a 1-year high of $51.32. The stock has a 50-day moving average of $48.12 and a 200-day moving average of $46.67. The company’s market cap is $1.619 billion.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last released its earnings data on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.04. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $229.32 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. On average, analysts predict that Integra Lifesciences Holdings Corp will post $2.94 earnings per share for the current fiscal year.

IART has been the subject of a number of recent research reports. Analysts at Oppenheimer reiterated an “outperform” rating on shares of Integra Lifesciences Holdings Corp in a research note on Wednesday, August 6th. They now have a $57.00 price target on the stock, up previously from $55.00. Analysts at Jefferies Group raised their price target on shares of Integra Lifesciences Holdings Corp from $54.00 to $57.00 in a research note on Wednesday, August 6th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Integra Lifesciences Holdings Corp currently has an average rating of “Hold” and a consensus target price of $52.57.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.

Receive News & Ratings for Integra Lifesciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences Holdings Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.